with EU regulations.

Combination products, which are defined as products that combine a drug and a device, bring unique regulatory challenges, especially concerning their classification, labeling, and documentation requirements. Under Article 117 of the EU MDR, specific requirements must be met, and as such, manufacturers need to be prepared to meet the comprehensive data requirements associated with both drug and device components.

Prior to undertaking registration in EUDAMED, it is paramount to assess whether your product aligns with the definitions outlined in the EU MDR and to identify the components that will necessitate distinct regulatory pathways. A deep understanding of the General Safety and Performance Requirements (GSPR) in Annex II is essential here, as they set the foundational standards for the safety and effectiveness of combined products.

Step 2: Preparation of Required Documentation for EUDAMED Registration

Preparing the necessary documentation is a crucial step toward EUDAMED registration. The primary documents required include the following:

• Design Dossier: This should detail the design, development, and performance data of the combination product. Emphasize compliance with the GSPR.
• Clinical Evaluation Report (CER): Ensure that your CER considers both the device and medicinal aspects of the combination product. Reference data should encompass clinical studies and post-market surveillance results.
• Risk Management File: Include a comprehensive risk assessment that complies with ISO 14971, demonstrating how risks associated with both components are identified and mitigated.
• Labeling and Instructions for Use (IFU): Develop labeling that clearly defines the use and purpose of both the drug and device components, complying with Article 10 of EU MDR.

Each document must satisfy the formal documentation expectations set forth by the EU regulations. Document control is critical; therefore, it is advisable to implement a quality management system that complies with relevant standards, such as ISO 13485. Documentation should be reviewed regularly for relevance and accuracy to maintain regulatory readiness.

Step 3: Engagement with a Notified Body

Manufacturers of combination products must engage with a Notified Body to validate compliance with the applicable regulatory requirements. Choosing the right Notified Body is foundational; it should possess expertise in both device and pharmaceutical regulations. The selection process includes:

• Assessment of Notified Body’s Scope: Check whether the Notified Body has the necessary scope of designation concerning combination products.
• Submission of Technical Documentation: Prepare for the submission process, ensuring all documentation is precise, coherent, and aligned with EU requirements.
• Communication of Regulatory Strategy: Maintain open lines of communication with your Notified Body to clarify expectations and timelines.

The Notified Body will assess the conformity of the combination product against the applicable harmonized standards and regulatory requirements. Successful engagement with them entails preparation for audits and assessments and prompt responses to any queries related to the product.

Step 4: Entering Data into EUDAMED

Once diligent preparations and successful evaluations are in place, the next step is to enter relevant product data into EUDAMED. This phase necessitates an in-depth understanding of the platform and its requirements:

As part of the registration process, companies must:

• Create a Unique Device Identifier (UDI): Ensure to generate a UDI for the combination product, which is critical for traceability and regulatory tracking.
• Develop and Submit Device and Clinical Data: In EUDAMED, you must provide detailed information regarding the product’s characteristics, clinical data, intended use, and the results of clinical evaluations. Make certain that data provided regarding the device and medicinal ingredient clearly complements each other.
• Compliance with Governance Requirements: Ensure adherence to the governance structure related to data input, incorporating all necessary stakeholders in the documentation process.

It is crucial to select appropriate technical teams trained in EUDAMED functionality to support data entry and accuracy. Any discrepancies or inaccuracies may lead to significant regulatory repercussions and hinder market access.

Step 5: Post-Approval Monitoring and Compliance Commitments

Following successful registration and market entry via EUDAMED, manufacturers must continue to uphold regulatory commitments through continuous monitoring and compliance management. Key post-approval actions include:

• Vigilance Reporting: It is mandatory to report any serious incidents related to the combination product to competent authorities as part of vigilance obligations. Establish a robust adverse event reporting system.
• Periodic Safety Update Reports (PSURs): Regularly prepare and submit PSURs that demonstrate ongoing compliance and product safety over time.
• Updating EUDAMED Information: Ensure that any changes to the technical documentation, intended use, or product characteristics are promptly updated in EUDAMED to reflect real-time data.

Engaging in proactive risk management and quality assurance processes throughout the product lifecycle is essential to maintain compliance with regulatory expectations. Continuous training and updates for the regulatory affairs team can foster a culture of compliance and enhance operational readiness for future submissions.

In conclusion, achieving EUDAMED registration readiness for combination products requires a structured, actionable approach focused on regulatory compliance, thorough documentation, and an understanding of governance principles. By following this step-by-step guide, stakeholders can better prepare for successfully navigating the complex regulatory landscape.